Market News
5 min read | Updated on July 25, 2025, 08:10 IST
SUMMARY
Stocks to Watch: Shares of select sectors will be in focus after India and the UK on Thursday signed a landmark trade deal to boost two-way trade by eliminating tariffs on cars, textiles, whisky, and a range of other products.
The GIFT NIFTY futures suggest that the NIFTY50 index will open 104 points lower. | Image: Shutterstock
Prime Minister Narendra Modi and his UK counterpart Keir Starmer firmed up the 'Vision 2035' strategy to expand ties in areas of defence, technology, clean energy, and migration.
The Comprehensive Economic and Trade Agreement (CETA), inked by Commerce Minister Piyush Goyal and his UK counterpart Jonathan Reynolds in the presence of the two prime ministers, seeks to enhance bilateral trade by around $34 billion annually besides ensuring better market access.
However, sequentially, the net profit fell 9.7% quarter-on-quarter (QoQ) from ₹1,170.4 crore in Q4FY25.
The company had reported a consolidated net profit of ₹3,460.19 crore in the quarter ended on June 30, 2024, it said in a regulatory filing.
Its total income rose to ₹14,823.98 crore in the quarter under review, jumping 13.22% YoY from ₹13,092.44 crore in the same period a year ago.
Its revenue from operations in the April-June period advanced 15% to ₹142 crore from ₹124 crore in the year-ago period.
Electricity volumes in the first quarter rose 15% to 32.4 billion units, and the company traded 52.7 lakh renewable energy certificates, up 149% annually.
Its net interest income, the difference between interest earned and interest expended, advanced 22% in Q1 to ₹10,227 crore from ₹8,365 crore in the year-ago period.
Bajaj Finance's fees and commission income came in at ₹1,784 crore, up 17% from ₹1,524 crore in the corresponding period last year.
In the corresponding period a year ago, it had clocked a profit of ₹519.52 crore.
The insurance company's net premium income stood at ₹17,178.50 crore in the quarter under review, jumping 13.72% YoY from ₹15,105.48 crore in the June quarter of FY25.
The subsidiaries of the company, Sun Pharmaceutical Industries, Inc. (SPII) and Taro Pharmaceuticals USA, Inc., have signed a settlement agreement with the End Purchaser Plaintiffs in the In re Generic Pharmaceuticals Pricing Antitrust Litigation in the Eastern District of Pennsylvania, US, the Mumbai-based drugmaker said in a regulatory filing.
The Tamil Nadu-based bank had earned a net profit of ₹458.65 crore during the corresponding quarter of last financial year.
For the year ending March 31, 2025, the net profit of the bank stood at ₹1,941.64 crore.
The total income for the quarter under review grew to ₹3,015.80 crore from ₹2,672.88 crore registered in the corresponding quarter of last financial year. For the financial year ending March 31, 2025, the total income was at ₹11,507.59 crore.
About The Author